Posted by Michael Wonder on 10 Jan 2023
Qulipta now approved by Health Canada for the preventive treatment of episodic migraine in adults
9 January 2023 - Qulipta is the first and only oral calcitonin gene-related peptide receptor antagonist (gepant) specifically developed for the preventive treatment of episodic migraine.
AbbVie announced today that Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (<15 migraine days per month) in adults.
